Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.

European journal of clinical pharmacology - 1 Jan 2011

Kummer Oliver, Hammann Felix, Moser Claudine, Schaller Olivier, Drewe Jürgen, Krähenbühl Stephan

Abstract excerpt

PURPOSE: The main metabolic pathways of oxycodone, a potent opioid analgetic, are N-demethylation (CYP3A4) to inactive noroxycodone and O-demethylation (CYP2D6) to active oxymorphone. We performed a three-way, placebo-controlled, double-blind cross-over study to assess the pharmacokinetic and pha...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics, Opioid
Share to Cross-Over Studies
Share to Cytochrome P-450 CYP2D6 Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A Inhibitors

Share to Drug Interactions

Share to Pain Measurement

Share to Paroxetine

Share to Placebos

Source

Identifiers

PMID: 20857093
DOI: 10.1007/s00228-010-0893-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20857093-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.PMID 20857093Read ↗

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.Semantic proximity Read ↗

The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.Semantic proximity Read ↗

The Hypoalgesic Effect of Oxycodone in Human Experimental Pain Models in Relation to the CYP2D6 Oxidation PolymorphismSemantic proximity Read ↗

Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective MetabolismSemantic proximity Read ↗

Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration.Semantic proximity Read ↗

Miotic action of tramadol is determined by CYP2D6 genotype.Semantic proximity Read ↗

The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.Semantic proximity Read ↗

Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.Semantic proximity Read ↗

Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.Semantic proximity Read ↗

Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?Semantic proximity Read ↗

The role of active metabolites in dihydrocodeine effects.Semantic proximity Read ↗

Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.